AbbVie Inc. (NYSE:ABBV) is a prominent player in the pharmaceutical industry, known for its focus on developing innovative therapies. The company is set to release its third-quarter earnings on October 31, 2025. Analysts predict earnings per share (EPS) of $1.77 and revenue of approximately $15.59 billion. AbbVie competes with other pharmaceutical giants like Eli Lilly, Merck, and Gilead.
Ahead of its earnings report, AbbVie is rated as a Strong Buy. The company is expected to achieve revenue growth surpassing the sector median. AbbVie consistently delivers results that exceed expectations, maintaining strong free cash flow margins. This performance is supported by significant investments in research and development, which are crucial for driving future growth.
Despite a challenging year for the industry, AbbVie has managed to maintain its strong track record. The company has exceeded earnings expectations in each of the last four quarters, with an average earnings surprise of 2.46%. However, near-term profitability may be impacted by significant in-process research and development expenses related to acquisitions.
AbbVie's valuation metrics reveal interesting insights. The company has a high price-to-earnings (P/E) ratio of approximately 107.36, indicating that investors are willing to pay over 107 times the company's earnings over the past twelve months. The price-to-sales ratio stands at about 6.92, suggesting that investors are paying nearly 7 times the company's sales.
The current ratio is approximately 0.74, suggesting potential challenges in covering short-term liabilities with short-term assets. Despite these concerns, the Dividend Discount Model (DDM) suggests AbbVie is significantly undervalued, with a potential 27% increase in its stock price over the next year.
